Quantcast

Latest Archimedes Pharma Stories

2010-10-13 03:00:00

STOCKHOLM, October 13, 2010 /PRNewswire/ -- Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA) for its product candidate Nefecon (PL-56) for patients with IgA nephropathy, also referred to as Berger's Disease. This program is presently in clinical development phase II. Johan Haggblad, Managing director of Pharmalink AB said: "Today's news marks a significant milestone for Pharmalink, and...

2010-10-12 07:58:00

READING, England and BEDMINSTER, N.J., Oct. 12 /PRNewswire/ -- Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, today announced publication of results from a Phase III, long-term safety, tolerability and consistency of effect, clinical study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP). The article, entitled "Long-term safety, tolerability, and consistency of effect of...

2010-10-05 11:13:00

In the news release, Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain, issued 04-Oct-2010 by Archimedes Pharma over PR Newswire, we are advised by the company that the second paragraph, last sentence, the link should read "http://www.ncbi.nlm.nih.gov/pubmed/20800358" rather than "http://www.jpain.org/" as originally issued inadvertently. The...

2010-08-23 06:17:00

READING, England and BEDMINSTER, N.J., Aug. 23 /PRNewswire/ -- Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, announced today the location of its new US headquarters in Bedminster, New Jersey. Archimedes has offices in a number of European countries and markets a range of therapeutics in Europe. The opening of its US office marks the continued expansion of the company's global commercial presence. The New Jersey...

2010-06-25 04:31:00

READING, England, June 25, 2010 /PRNewswire/ -- Archimedes Pharma ("Archimedes"), a leading specialty pharma company, today announced that its lead product, PecFent*, has received a Positive Opinion from the Committee for Human Medicinal Products (CHMP), of the European Medicines Agency (EMA). The CHMP is recommending PecFent, an innovative fentanyl nasal spray, be authorised for marketing in European Union countries for the treatment of breakthrough cancer pain (BTCP) - sudden,...

2010-03-02 01:00:00

READING, England, March 2, 2010 /PRNewswire/ -- - Appoints new Chief Executive Officer to Accelerate Growth of Business - US Commercial Operations to be Established Archimedes Pharma ("Archimedes"), the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg...

2009-10-26 03:00:00

STOCKHOLM, October 26 /PRNewswire/ -- - Japanese Grant Supports Asian Partnering Programme Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China. Pharmalink's...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.